Skip to content
BiologicalX

Comparison

Fisetin vs Thymosin Alpha-1

Side-by-side of Fisetin and Thymosin Alpha-1. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.

Effects at a glance

Fisetin

  • Flavonoid found in strawberries; most potent natural senolytic in screening assays (Yousefzadeh 2018)
  • Hickson 2019 confirmed reduced senescent-cell burden in human adipose tissue at 20 mg/kg pulsed for 2 days
  • Pulsed Mayo protocol (20 mg/kg/day x 2 days monthly) is the only dose with human biomarker evidence
  • Daily low-dose (100-500 mg) is mechanistically weaker but commonly used
  • Low oral bioavailability; with-fat dosing modestly improves absorption
  • Active cancer is a relative contraindication pending clearer polyphenol-treatment data

Thymosin Alpha-1

  • 28-amino-acid synthetic peptide identical to thymic-derived immunomodulator
  • Approved in over 35 countries as Zadaxin for hepatitis B, hepatitis C adjunct, and immune support
  • Not FDA approved in US; compounded by 503A/503B pharmacies for off-label immune support
  • Modulates T-cell maturation, NK activity, and Th1 polarization in immunocompromised states
  • Standard label dose: 1.6 mg subcutaneously twice weekly
  • Cleanest safety profile in the peptide class with hundreds of regulated trials behind it

Side-by-side

Attribute Fisetin Thymosin Alpha-1
Category supplement peptide
Also known as 3,7,3',4'-tetrahydroxyflavone Talpha1, Ta1, Zadaxin, Thymalfasin
Half-life (hr) 2 2
Typical dose (mg) 500 1.6
Dosing frequency pulsed 2 days/month (Mayo protocol) or daily continuous (empirical) 2x weekly
Routes oral subcutaneous, intramuscular
Onset (hr) 1 24
Peak (hr) 4 168
Molecular weight 286.24 3108.32
Molecular formula C15H10O6 C129H215N33O55
Mechanism Senolytic via Bcl-2 family inhibition (Bcl-xL, Bcl-w); broad polyphenol with Nrf2 activation, mTOR inhibition at high concentrations, and antioxidant effects. Synthetic peptide modulator of innate and adaptive immunity. Promotes T-cell maturation and CD4/CD8 production, modulates Th1/Th2 balance, stimulates NK cell activity, and modulates TLR2/TLR9 signaling in dendritic cells.
Legal status OTC dietary supplement Approved in 35+ countries as Zadaxin (hepatitis B, hepatitis C adjunct, immune support); not FDA approved in US; compounded by 503A/503B pharmacies for off-label use; not on WADA Prohibited List
WADA status allowed unknown
DEA / Rx OTC supplement Rx only via international approval or US compounding (no controlled-substance schedule)
Pregnancy Insufficient data Not recommended; insufficient data
CAS 528-48-3 62304-98-7
PubChem CID 5281614 16130571
Wikidata Q230614 Q913854

Safety profile

Fisetin

Common side effects

  • mild GI upset
  • headache (rare)

Contraindications

  • active cancer (theoretical, polyphenol interactions)
  • pregnancy and lactation (insufficient data)
  • concurrent CYP3A4-sensitive medications

Interactions

  • statins (CYP3A4 substrates): theoretical reduction in statin clearance at high fisetin doses(minor)
  • warfarin: theoretical CYP-mediated interaction; monitor INR if combining(moderate)
  • other senolytics (rapamycin, dasatinib + quercetin): additive senolytic effect; pairing is investigational(minor)

Thymosin Alpha-1

Common side effects

  • mild injection-site irritation (rare)
  • transient mild fatigue (rare)
  • occasional headache (rare)

Contraindications

  • pregnancy
  • lactation
  • active organ transplant rejection therapy
  • systemic immunosuppression for autoimmune disease (relative)
  • severe active autoimmune disease (caution)

Interactions

  • interferon-alpha: additive immune effect; used clinically in approved combination protocols(minor)
  • calcineurin inhibitors (cyclosporine, tacrolimus): theoretical destabilization of immunosuppression; avoid(major)
  • antimetabolites (azathioprine, mycophenolate): theoretical destabilization of immunosuppression; avoid(major)
  • vaccine administration: may augment vaccine response in elderly or immunocompromised; coordinate with clinician(minor)

Which Should You Take?

Fisetin comes out ahead for most readers on the criteria we weight: 2 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-B outcome catalogued. Thymosin Alpha-1 is the right call when one of the conditionals below applies.

  • If your priority is healthspan extension, pick Fisetin.
  • If your priority is focus or working memory, pick Fisetin.
  • If your priority is immune support, pick Thymosin Alpha-1.
  • If your priority is post-training recovery, pick Thymosin Alpha-1.

Edge case: If you want to avoid Approved in 35+ countries as Zadaxin (hepatitis B, hepatitis C adjunct, immune support); not FDA approved in US; compounded by 503A/503B pharmacies for off-label use; not on WADA Prohibited List, Fisetin is the more accessible choice.

Default choice: Fisetin. Lower friction to source, and broader goal coverage. Reach for Thymosin Alpha-1 only if your priority sits squarely in the goals it owns above.

This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.

Common questions

What is the difference between Fisetin and Thymosin Alpha-1?

Fisetin and Thymosin Alpha-1 differ in category (supplement vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.

Which has a longer half-life, Fisetin or Thymosin Alpha-1?

Fisetin half-life is 2 hours; Thymosin Alpha-1 half-life is 2 hours.

Can you stack Fisetin with Thymosin Alpha-1?

Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.

Go deeper